24.1.2009 EN Official Journal of the European Union L 21/53
COMMISSION DECISION
of 18 December 2008
on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2009 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council on substances that deplete the ozone layer
(notified under document number C(2008) 8398)
(Only the Dutch, English, French, German, Italian, Slovenian and Spanish texts are authentic)
(2009/52/EC)
THE COMMISSION OF THE EUROPEAN COMMUNITIES
,
Having regard to the Treaty establishing the European Community,
Having regard to Regulation (EC) No 2037/2000 of the European Parliament and of the Council of 29 June 2000 on substances that deplete the ozone layer (1), and in particular Article 3(1) thereof,
Whereas:
(1) The Community has already phased out the production and consumption of chlorofluorocarbons, other fully halogenated chlorofluorocarbons, halons, carbon tetrachloride, 1,1,1-trichloroethane, hydrobromofluorocarbon and bromochloromethane.
(2) Each year the Commission is required to determine essential uses for these controlled substances, the quantities that may be used and the companies that may use them.
(3) Decision IV/25 of the Parties to the Montreal Protocol on substances that deplete the ozone layer, hereinafter ‘the Montreal Protocol’, sets out the criteria used by the Commission for determining any essential uses and authorises the production and consumption necessary to satisfy essential uses of controlled substances in each Party.
(4) The Parties to the Montreal Protocol authorised the production in the European Community of 22 tonnes of chlorofluorocarbons (CFCs) in 2009 for the manufacturing and use of metered-dose inhalers (MDIs) qualifying for essential uses of CFCs as defined in Decision IV/25.
(5) Decision XIX/18 of the Parties to the Montreal Protocol authorises the production and consumption necessary to satisfy essential uses of controlled substances listed in Annexes A, B and C (Group II and III substances) of the Montreal Protocol for laboratory and analytical uses as listed in Annex IV to the report of the Seventh Meeting of the Parties, subject to the conditions set out in Annex II to the report of the Sixth Meeting of the Parties, as well as Decisions VII/11, XI/15 and XV/5 of the Parties to the Montreal Protocol. Decision XVII/10 of the Parties to the Montreal Protocol authorises the production and consumption of the controlled substance listed in Annex E of the Montreal Protocol necessary to satisfy laboratory and analytical critical uses of methyl bromide.
(6) Pursuant to paragraph 3 of Decision XII/2 of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free MDIs, all Member States have notified the United Nations Environment Programme the active ingredients for which chlorofluorocarbons (CFCs) are no longer essential for the manufacture of MDIs for placing on the market of the European Community.
(7) Article 4(4)(i)(b) of Regulation (EC) No 2037/2000 prevents CFCs from being used and placed on the market unless they are considered essential under the conditions described in Article 3(1) of that Regulation. These non-essentiality determinations have therefore reduced the demand for CFCs used in MDIs that are placed on the market of the European Community. In addition, Article 4(6) of Regulation (EC) No 2037/2000 prevents CFC-MDI products being imported and placed on the market unless the CFCs in these products are considered essential under the conditions described in Article 3(1).
(8) The Commission has published a notice (2) to those companies in the Member States that request consideration by the Commission for the use of controlled substances for essential uses in the Community in 2009 and has received declarations on intended essential uses of controlled substances for 2009.
(9) The measures provided for in this Decision are in accordance with the opinion of the Management Committee established by Article 18(1) of Regulation (EC) No 2037/2000,
1.   The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) subject to Regulation (EC) No 2037/2000 which may be used for essential medical uses in the Community in 2009 shall be 21 360,00 ozone depleting potential (ODP) kilograms.
2.   The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) and Group II (other fully halogenated chlorofluorocarbons) subject to Regulation (EC) No 2037/2000 which may be used for essential laboratory and analytical uses in the Community in 2009 shall be 60 280,8 ODP kilograms.
3.   The quantity of controlled substances of Group III (halons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory and analytical use in the Community in 2009 shall be 115,7 ODP kilograms.
4.   The quantity of controlled substances of Group IV (carbon tetrachloride) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory and analytical uses in the Community in 2009 shall be 129 390,8 ODP kilograms.
5.   The quantity of controlled substances of Group V (1,1,1-trichloroethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory and analytical uses in the Community in 2009 shall be 355,65 ODP kilograms.
6.   The quantity of controlled substances of Group VI (methyl bromide) subject to Regulation (EC) No 2037/2000 that may be used for laboratory and analytical critical uses in the Community in 2009 shall be 36,3 ODP kilograms.
7.   The quantity of controlled substances of Group VII (hydrobromofluorocarbons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory and analytical uses in the Community in 2009 shall be 57,96 ODP kilograms.
8.   The quantity of controlled substances of group IX (bromochloromethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory and analytical uses in the Community in 2009 shall be 11,088 ODP kilograms.
The chlorofluorocarbon metered-dose inhalers listed in Annex I shall not be placed on markets where the competent authority has determined chlorofluorocarbons for metered-dose inhalers on those markets to be non-essential.
During the period 1 January to 31 December 2009 the following rules shall apply:
1. The allocation of essential medical use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 shall be to the companies indicated in Annex II.
2. The allocation of essential laboratory and analytical use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 and other fully halogenated chlorofluorocarbons shall be to the companies indicated in Annex III.
3. The allocation of essential laboratory and analytical use quotas for halons shall be to the companies indicated in Annex IV.
4. The allocation of essential laboratory and analytical use quotas for carbon tetrachloride shall be to the companies indicated in Annex V.
5. The allocation of essential laboratory and analytical use quotas for 1,1,1-trichloroethane shall be to the companies indicated in Annex VI.
6. The allocation of laboratory and analytical critical use quotas for methyl bromide shall be to the companies indicated in Annex VII.
7. The allocation of essential laboratory and analytical use quotas for hydrobromofluorocarbons shall be to the companies indicated in Annex VIII.
8. The allocation of essential laboratory and analytical use quotas for bromochloromethane shall be to the companies indicated in Annex IX.
9. The essential use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115, other fully halogenated chlorofluorocarbons, carbon tetrachloride, 1,1,1-trichloroethane, hydrobromofluorocarbons and bromochloromethane and the laboratory and analytical critical use quotas for methyl bromide shall be as set out in Annex X.
This Decision shall apply from 1 January 2009 and shall expire on 31 December 2009.
This Decision is addressed to the following undertakings:
Acros Organics bvba
Janssen Pharmaceuticalaan 3a
B-2440 Geel
Airbus France
316, route de Bayonne
F-31300 Toulouse
Carlo Erba Réactifs-SDS
Z.I. de Valdonne, BP 4
F-13124 Peypin
Chiesi Farmaceutici SpA
Via Palermo 26/A
I-43100 Parma
CNRS — Groupe de physique des solides
Université Paris 7 Denis Diderot et Paris 6
Pierre et Marie Curie
F-75251 Paris Cedex 5
Harp International
Gellihirion Industrial Estate Rhondda,
Cynon Taff
Pontypridd CF37 5SX
UNITED KINGDOM
Honeywell Specialty Chemicals
Wunstorfer Straße 40
Postfach 10 02 62
D-30918 Seelze
Ineos Fluor Ltd
PO Box 13, The Heath
Runcorn Cheshire WA7 4QF
UNITED KINGDOM
Institut scientifique de service public
Rue du Chéra 200
B-4000 Liège
LGC Standards GmbH
Mercatorstraße 51
D-46485 Wesel
Mallinckrodt Baker BV
Teugseweg 20
7418 AM Deventer
Nederland
Merck KGaA
Frankfurter Straße 250
D-64271 Darmstadt
Mikro + Polo d.o.o.
Zagrebška cesta 22
SI-2000 Maribor
Ministry of Defense
Defence Fuel Lubricants and Chemicals
PO Box 10 000
1780 CA Den Helder
Nederland
Panreac Química SA
Pol. Ind. Pla de la Bruguera, C/Garraf, 2
E-08211 Castellar del Vallès
Barcelona
Sigma Aldrich Chimie SARL
80, rue de Luzais
L’Isle d’Abeau Chesnes
F-38297 Saint-Quentin-Fallavier
Sigma Aldrich Company
The Old Brickyard, New Road
Gillingham SP8 4XT
UNITED KINGDOM
Sigma Aldrich Laborchemikalien
Wunstorfer Straße 40
Postfach 10 02 62
D-30918 Seelze
Sigma Aldrich Logistik GmbH
Riedstraße 2
D-89555 Steinheim
Solvay Organics GmbH
Hans-Böckler-Allee 20
D-30173 Hannover
Tazzetti Fluids SRL
Corso Europa 600/a
I-10088 Volpiano (TO)
Valeas SpA Pharmaceuticals
Via Vallisneri 10
I-20133 Milano
Valvole Aerosol Research Italiana (VARI)
SpA — LINDAL Group Italia
Via del Pino 10
I-23854 Olginate (LC)
VWR ISAS
201, rue Carnot
F-94126 Fontenay-sous-Bois